Tenderwize
Retour à la recherche

Non-Exclusive Pharmaceutical Discount Agreement for Formoterol/Glycopyrronium/Budesonid (ATC R03AL11) via Open-House Model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 306 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Formoterol/Glycopyrronium/Budesonid (ATC-Code nach WHO: R03AL11)

55/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

55 / 100

Complexité

40 / 100

Facteurs de risque

Actual demand is unknown and depends on prescription behavior, patient numbers, and pharmacy stocking. No minimum volum...

The buyer may terminate the open-house process early if exclusive discount agreements are concluded, typically 8-12 mon...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of pharmaceutical product Formoterol/Glycopyrronium/Budesonid (ATC R03AL11)
  • Non-exclusive discount agreement under §130a Abs. 8 SGB V
Afficher le résumé complet

Non-exclusive pharmaceutical discount agreement (Rabattvertrag) for the active ingredient Formoterol/Glycopyrronium/Budesonid (ATC R03AL11) via an Open-House model. The agreement is open to all eligible pharmaceutical entrepreneurs, with no guaranteed volume or exclusivity. Contract ends 30.06.2027. First submission deadline: 02.06.2025; further deadlines as per attached schedule.

Risques

Actual demand is unknown and depends on prescription behavior, patient numbers, and pharmacy stocking. No minimum volum...

The buyer may terminate the open-house process early if exclusive discount agreements are concluded, typically 8-12 mon...

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) per §4 Abs.18 AMG

Eligibility

  • Must submit declarations: exclusion grounds and Russia sanctions

Administrative

  • Communication and submission via DTVP portal

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria (open house).

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-Exclusive Pharmaceutical Discount Agreement for Formoterol/Glycopyrronium/Budesonid (ATC R03AL11) via Open-House Model

Supply of pharmaceutical product under a non-exclusive discount agreement. No guaranteed minimum volume. Contract duration until 30.06.2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria (open house).

Date limite

Deadline Jun 30, 2027

Détails de la procédure

Date de publication
29 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
277852-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30